UnknownPhase 2NCT05200754
Trial With or Without Infusion of SARS-CoV-2 Antibody Containing Plasma in High-Risk Patients With COVID-19
Studying Severe acute respiratory syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Carsten Müller-Tidow
- Principal Investigator
- Carsten Mueller-Tidow, Prof. Dr.University Hospital Heidelberg
- Intervention
- Convalescent/Vaccine-boosted Plasma (CP/PVP)(other)
- Enrollment
- 174 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2020 – 2022
Study locations (16)
- Charité Universtitätsmedizin Berlin, Berlin, Germany
- Klinikum Bremen-Mitte - Klinik für Innere Medizin I, Bremen, Germany
- Klinikum Chemnitz Medizinische Klinik III, Chemnitz, Germany
- Klinikum Darmstadt Medizinische Klinik II, Darmstadt, Germany
- Universitätsklinikum Dresden Medizinische Klinik und Poliklinik I, Dresden, Germany
- Universitätsklinikum Essen Klinik für Infektiologie, Essen, Germany
- Klinikum Frankfurt (Oder) - Medizinische Klinik I, Frankfurt (Oder), Germany
- Universitätsklinikum Frankfurt Medizinische Klinik II, Frankfurt am Main, Germany
- Universitätsklinikum Freiburg, Allgemeine Infektion-Ambulanz / Klinik für Innere Medizin II, Freiburg im Breisgau, Germany
- Universitätsklinikum Hamburg-Eppendorf Zentrum für Innere Medizin I, Hamburg, Germany
- Universitätsklinikum Heidelberg Innere Medizin V, Heidelberg, Germany
- Thoraxklinik Heidelberg - Studienzentrum Pneumologie, Heidelberg, Germany
- Klinikum Herford, Herford, Germany
- Klinikum Leverkusen - Medizinische Klinik 3, Leverkusen, Germany
- Klinikum Hochsauerland, Meschede, Germany
- +1 more locations on ClinicalTrials.gov
Collaborators
German Federal Ministry of Education and Research · Institut für Klinische Transfusionsmedizin und Zelltherapie Heidelberg gGmbH
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05200754 on ClinicalTrials.govOther trials for Severe acute respiratory syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06099795Evaluation of Concordance Between Exhaled Air Test (eBAM-CoV) and RT-PCR to Detect SARS-CoV-2Centre Hospitalier Universitaire de Nīmes
- RECRUITINGPHASE4NCT06585241A Study to Investigate the Immunogenicity and Safety of mRNA COVID-19 Variant-containing Vaccine FormulationsModernaTX, Inc.
- RECRUITINGNCT06168019Influenza & COVID-19 Obstetric and Perinatal Epidemiology Study in IndiaBoston University
- RECRUITINGEARLY PHASE1NCT05656105Positron Emission Tomography (PET) Imaging of Neuroinflammation in Patients With Neurological Dysfunction After Severe Acute Respiratory Syndrome Coronavirus 2 (SARS CoV 2) InfectionUniversity of Alabama at Birmingham
- RECRUITINGNCT05892549COVID-19: Early Detection of Worsening by Voice and Respiratory Pattern CharacteristicsDirection Centrale du Service de Santé des Armées
- RECRUITINGNANCT05566483Physiology of Long COVID-19 and the Impact of Cardiopulmonary Rehabilitation on Quality-of-Life and Functional CapacityUniversity of Colorado, Denver
- ACTIVE NOT RECRUITINGNCT05787964Immunity to Infection in Healthy Participants and Participants With CancerUniversity Hospital Tuebingen
- RECRUITINGPHASE2, PHASE3NCT05543616A Study to Learn About Variant-Adapted COVID-19 RNA Vaccine Candidate(s) in Healthy ChildrenBioNTech SE